Charateristics | Patients (n = 96) No.(%) |
---|---|
Sex | Â |
Male | 34 (35.4Â %) |
Female | 62 (64.6Â %) |
Age(year), median(range) | 54 (26–79) |
aECOG performance status | Â |
0–1 | 69 (71.9 %) |
2–3 | 27 (28.1 %) |
No. of brain lesions | Â |
1–4 | 32 (33.3 %) |
>4 | 64 (66.7Â %) |
Max size of brain lesions | Â |
<1Â cm | 75 (78.1Â %) |
>1Â cm | 21 (21.9Â %) |
Location of brain lesions | Â |
Brain stem mets | 13 (13.5Â %) |
Non-brain stem mets | 83 (86.5Â %) |
Other sites of metastatic disease | Â |
Yes | 61 (63.5Â %) |
No | 35 (36.5Â %) |
bEGFR mutation | Â |
Exon 19 | 45 (46.9Â %) |
Exon 21 | 51 (53.1Â %) |
First line systemic treatment | Â |
Chemotherapy | 61 (63.5Â %) |
cTKI | 35 (36.5Â %) |
Time of Brain radiotherapy | Â |
First line | 39 (40.6Â %) |
Delayed | 23 (24.0Â %) |
No dRT | 34 (35.4Â %) |